# AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer

Source: https://onco.cc/trials/nct07767994/  
OnCo record `nct07767994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.

## Summary

AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer is a phase 2 interventional study registered as NCT07767994 by First Affiliated Hospital Xi'an Jiaotong University, with a registry enrolment figure of 22 participants, started 2026-08-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: AK112, Gemcitabine, Cisplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Gallbladder Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ICORE-GBC
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07767994
- Phase: 2
- Setting: Single-Center, Single-Arm, Two-Stage, Prospective Phase II Clinical Study of AK112 Combined With GAP Regimen as Conversion Therapy for Locally Advanced Gallbladder Cancer
- Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT07767994: https://clinicaltrials.gov/study/NCT07767994

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07767994.json